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Abstract: 
 
The purpose of the study was to examine the effect of high-intensity exercise and carbohydrate 
supplementation (CHO) on plasma visfatin. On 2 separate days, 10 sprint-trained males (age = 
26.4 ± 5.3 yr; Ht = 1.77 ± 0.03 m; Wt = 78.78 ± 9.10 kg; BF% = 13.96 ± 7.28%) completed 4, 3-
min bouts of cycling at 50% mean anaerobic power, with 6 min of rest between bouts. On CHO 
day, subjects ingested 50g of CHO 30 min before exercise. On control day, subjects ingested a 
sugar-free drink (CON) 30 min before exercise. Blood was drawn before supplementation, 15 
min before exercise, before and after each exercise bout, and 15 and 30 min post exercise. 
Visfatin, glucose, and insulin were determined. Truncal fat was assessed by dual energy x-ray. 
Visfatin was not significantly different between treatments (CHO vs CON) at any time point (p = 
0.163), and was not significantly altered by exercise (p = 0.692). Insulin [25.65 vs 8.35 mU/l, 
CHO vs CON, respectively] and glucose [138.57 vs 98.10 mg/dl, CHO vs CON, respectively] 
were significantly elevated after CHO ingestion and remained elevated throughout the first half 
of exercise. Baseline visfatin was significantly correlated with truncal fat (r2 = 0.7782, p < 0.05). 
Visfatin was correlated to truncal fat in sprint-trained males, but was not altered by exercise or 
CHO supplementation. 
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Abstract  
The purpose of the study was to examine the effect of high-
intensity exercise and carbohydrate supplementation (CHO) on 
plasma visfatin. On 2 separate days, 10 sprint-trained males (age 
= 26.4 ± 5.3 yr; Ht = 1.77 ± 0.03 m; Wt = 78.78 ± 9.10 kg; BF% 
= 13.96 ± 7.28%) completed 4, 3-min bouts of cycling at 50% 
mean anaerobic power, with 6 min of rest between bouts. On 
CHO day, subjects ingested 50g of CHO 30 min before exercise.  
On control day, subjects ingested a sugar-free drink (CON) 30 
min before exercise.  Blood was drawn before supplementation, 
15 min before exercise, before and after each exercise bout, and 
15 and 30 min post exercise. Visfatin, glucose, and insulin were 
determined. Truncal fat was assessed by dual energy x-ray. 
Visfatin was not significantly different between treatments 
(CHO vs CON) at any time point (p = 0.163), and was not sig-
nificantly altered by exercise (p = 0.692). Insulin [25.65 vs 8.35 
mU/l, CHO vs CON, respectively] and glucose [138.57 vs 98.10 
mg/dl, CHO vs CON, respectively] were significantly elevated 
after CHO ingestion and remained elevated throughout the first 
half of exercise. Baseline visfatin was significantly correlated 
with truncal fat (r2 = 0.7782, p < 0.05). Visfatin was correlated 
to truncal fat in sprint-trained males, but was not altered by 
exercise or CHO supplementation.  
 
Key words: Visfatin, glucose, exercise, carbohydrate supple-
mentation, insulin. 
 
 
Introduction 
 
Visfatin is a protein preferentially expressed in visceral 
fat that has been implicated in multiple cellular functions 
(Rongvaux et al. 2002; Samal et al. 1994; Xie et al. 2007).  
These cellular functions include inflammation, regulation 
of nicotinamide adenine dinucleotide (NAD) biosynthesis, 
and glucose metabolism. Recently, the role of visfatin in 
glucose metabolism has generated considerable interest 
since the underlying mechanism related to the influence 
of visfatin on glucose uptake has yet to be identified. One 
popular proposed mechanism, displayed in hyperglycemic 
mice and human osteoblasts, is the visfatin-mediated 
increase in glucose uptake via increasing tyrosine phos-
phorylation of the insulin receptor, insulin receptor sub-
strates 1 and 2 (IRS-1, IRS-2), and phosphatidylinositol 
3-kinase (PI3K) (Xie et al. 2007). This mechanism may 
contribute to the restoration of insulin pathway sensitivity 
observed in hyperglycemic states (Choi et al. 2007; 
Fukuhara et al. 2005; Haider et al. 2006).  Moreover, 
visfatin-mediated glucose uptake was observed to be 
dose-dependent in human mesangial cells. This effect of 
visfatin may be a result of visfatin’s ability to non-
competitively bind to the insulin receptor (Song et al. 
2008). While this evidence suggests that visfatin influ-
ences glucose uptake on an intracellular level (possibly 
through its role in the NAD biosynthetic pathway), few 
studies have examined the extracellular relationship be-
tween plasma visfatin and glucose uptake.   
The interaction between plasma visfatin and extra-
cellular glucose regulation during exercise is not fully 
understood.  Following chronic aerobic exercise training, 
resting blood glucose decreases, which is paralleled by 
plasma visfatin levels (Brema et al. 2008; Choi et al. 
2007; Haider et al. 2006; Haus et al. 2009; Jorge et al. 
2011). Correspondingly, resting plasma visfatin levels are 
above acceptable levels in hyperglycemic individuals 
(Chang et al. 2011). These data suggest that in aerobic 
training studies completed in humans, plasma visfatin 
may be altering glucose regulation in a manner similar to 
insulin, since the plasma levels of both hormones respond 
to glucose similarly (Fukuhara et al. 2005; Revollo et al. 
2007). The effect of visfatin on glucose regulation in 
acute stress is also unclear, due to conflicting published 
results (Frydelund et al. 2007; Ghanbari-Niaki et al. 2010; 
Jurimae et al. 2009). In elite rowers, 2 hr of rowing per-
formed at 80% of heart rate reserve resulted in significant 
decreases in plasma visfatin and insulin, despite no signif-
icant change in blood glucose (Jurimae et al. 2009).  Con-
versely, visfatin was elevated more than two-fold after 
one exercise session including 7 bouts of 35 m sprint 
runs, and this elevation was mirrored by blood lactate, 
plasma insulin and blood glucose (Ghanbari-Niaki et al. 
2010). Finally, in healthy subjects that cycled for 3 hr at 
60% of VO2 max, there was no significant change in 
plasma visfatin, despite a significant decrease in plasma 
insulin and blood glucose (Frydelund-Larsen et al. 
2007).These seemingly contradictory results are likely 
due to the varying exercise protocols, as well as the vary-
ing subject characteristics. 
Although the exercise literature is murky, carbo-
hydrate intake studies can be used to provide some clarity 
in the response pattern of plasma visfatin compared to 
changing plasma glucose concentrations. Data from two 
carbohydrate intake studies in individuals with impaired 
insulin function suggest that plasma visfatin augments 
glucose uptake in a manner independent of insulin (Park 
et al. 2013; Rezvan et al. 2012). Research regarding car-
bohydrate intake and visfatin is limited, but available data 
suggest that glucose intake may suppress visfatin release; 
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however, the exact mechanism is still unclear (Bala et al. 
2011). To our knowledge, no study has controlled for 
both carbohydrate supplementation and exercise in order 
to assess the relationship between visfatin, insulin, and 
blood glucose. In order to gain a better understanding of 
how plasma visfatin may affect glucose uptake, it is nec-
essary to examine it in individuals without impaired insu-
lin function. Therefore, the purpose of this study was to 
further investigate the effect of acute exercise and carbo-
hydrate supplementation on plasma visfatin in an effort to 
further understand any role that visfatin may have in 
blood glucose regulation.  
 
Methods 
 
The University of North Carolina at Greensboro Institu-
tional Review Board approved all methods. Written in-
formed consent was received from all subjects, and a 
screening session was completed prior to the exercise 
sessions. During the screening session, abdominal circum-
ference and BMI were assessed, and a Wingate test was 
performed to determine mean power (MP). Resistance 
during the Wingate test was 7.5% of body weight. Mean 
power was calculated as MP (W) = load (Kg on flywheel) 
x average revolutions x 11.765. Wingate tests have been 
used in previous studies to determine workload for a high-
intensity interval exercise (Burgomaster et al. 2008; 
Franchini et al. 2016; Gibala et al. 2014) Resting heart 
rate (HR), blood pressure, medical history, and exercise 
history were also assessed. During the screening session, 
body composition and body fat distribution were deter-
mined by dual energy x-ray absorptiometry (DXA; Prodi-
gy Advanced, GE Lunar). Truncal fat was determined by 
DXA analysis and defined as any fat located below the 
neck and not on either limb. Truncal fat was assessed 
since it has been shown to be a direct indicator of the 
amount of visceral fat (Dwimartutie et al. 2010; Parikh et 
al. 2007). A 3-day dietary record was given to all sub-
jects, and was completed for the 3 days prior to each 
exercise session. Dietary records were analyzed for total 
caloric intake and macronutrient percentage using the My 
Fitness Pal software (MyFitnessPal, LLC, San Francisco, 
CA).     
After initially screening 12 individuals, 10 sprint-
trained males between the ages of 18 and 30 with less 
than 20% body fat qualified for the study. A group of 10 
subjects was determined via power analysis to be appro-
priate to yield a power of 0.80 with an alpha value of 
0.05. Sprint-trained was defined as participating in some 
form of high-intensity interval exercise at least 2 times 
per week for at least the last 4 weeks, using leg muscles 
that would be utilized for cycling. The majority of sub-
jects (n = 6) cycled regularly, four of whom cycled at 
least 100 miles per week. Furthermore, mean peak power 
for all subjects was 1068.6 ± 79.3 watts (W), which ranks 
above the 95th percentile (Maud and Shultz 1989).   
Subjects reported to the lab two times after over-
night fasts. An indwelling intravenous (IV) catheter was 
placed in the arm of the subject so that blood draws could 
be taken throughout the session. The first blood draw was 
taken 30 min prior to exercise. Immediately after the first 
blood draw, a supplement of either 50 g of carbohydrates 
(236 ml of Gatorade G01 Prime Solution; 0g of protein, 
0g of fat) or 236 ml of sugar-free Kool-Aid was adminis-
tered as the carbohydrate supplementation (CHO) or the 
placebo control (CON), respectively. The order of sup-
plement for each subject was determined by a coin flip to 
maintain randomness. Exercise began with a 6-min warm-
up at a standardized intensity of 50 W. After the warm-up, 
each subject completed four 3-min exercise bouts at 50% 
of MP, separated by 6 min of active recovery at an inten-
sity of 50 W. This timing and intensity was chosen based 
on a pilot study, as it elicited the necessary alterations in 
blood glucose (unpublished). Subjects were given water 
ad libitum, and water intake was not recorded.  Blood 
draws were taken immediately prior to and immediately 
after each high-intensity interval. The final draws were 
taken 15 min and 30 min post exercise.  These time points 
were chosen since exercise-induced changes in visfatin 
were shown to be reduced to baseline levels 30 min post 
exercise (Jurimae et al. 2009). Finally, in order for some 
subjects to be able to complete each bout, resistance was 
adjusted minimally; however, to control for any differ-
ence between exercise sessions, total work was calculated 
for each bout. Also, heart rate was recorded at each blood 
draw to further assess work. A 10-ml blood sample was 
obtained at each collection time point.   
Blood was collected into EDTA-treated tubes, cen-
trifuged at 3,000 rpm at 4 °C to separate plasma, and 
frozen at -80 °C until analysis. All blood variables were 
analyzed in duplicate. Plasma visfatin concentration was 
determined using a human visfatin enzyme-linked immu-
noassay (ELISA) (Adipobioscience, Santa Clara, CA). 
The sensitivity for this assay was 20-30 pg/ml, and the 
intra- and inter-assay CV were both less than 10%.  Plas-
ma insulin concentration was determined using a human 
ELISA kit (Mercodia, Winston-Salem, NC). The sensitiv-
ity for this assay was 1 mU/L, and the intra- and inter-
assay CV were both less than 5%. Finally, blood glucose 
concentration was determined using a human ELISA kit 
(Wako Diagnostics, Richmond, VA). The sensitivity of 
this assay was 0.7 mg/dl, and the intra- and inter-assay 
CV were both less than 5%. Blood lactate concentrations 
were analyzed using a modified version of the Hohorst 
enzymatic assay (Sigma Aldrich, St. Louis, MO) (Hohorst 
1957). 
Mean caloric intake, exercise workload, and HR 
were analyzed using a paired samples t-test for subjects 
between conditions (CHO and CON). Blood variables 
were analyzed using a 2 (CHO and CON) x 12 (time 
point) multivariate analysis of variance (MANOVA).  
When a main effect was found, post hoc testing was per-
formed using least squared differences. Blood variables 
were also compared between groups by determining rela-
tive area under the curve (AUC) using the trapezoidal 
integration method and analyzing AUC with a paired 
samples t-test. Finally, the relationship between plasma 
visfatin and body fat were correlated using a Pearson 
Product-Moment correlation coefficient. All data were 
analyzed using SPSS statistical package (Version 21, 
IBM, Minneapolis, MN) with statistical significance set at 
an alpha level of  ≤ 0.05. All results are presented as mean  
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± standard deviation unless otherwise noted. 
  
Results 
 
All subjects were of healthy weight based on both body 
fat percentage (13.96 ± 7.28 %) and BMI (24.19 ± 2.82 
kg·m-2). Furthermore, there were no statistically 
significant differences in total mean caloric intake (2398 
± 241 vs 2418 ± 303 kcal·day-1; p = 0.897) or in 
carbohydrate intake (1255.1 ± 241.2 vs 1305.4 ± 198.2 
kcal; p = 0.749), protein intake (667 ±  86 vs 709 ± 70 
kcal; p = 0.871)), or fat intake (545 ±  103 vs 487 ± 189 
kcal; p = 0.782) for the 3 days prior to either the CHO or 
CON trial, respectively. Insulin sensitivity was 
determined via homeostatic model assessment for insulin 
resistance and no significant difference was observed 
between CHO and CON (p = 0.721). Baseline plasma 
glucose (5.22 ± 0.75 vs 5.04 ± 1.03 mmol·l-1; p = 0.2367 
CHO vs CON, respectively), plasma insulin (5.14 ± 1.89 
vs 5.80 ± 4.12 mU·l-1; p = 0.5732 CHO vs CON, 
respectively), and plasma visfatin (15.35 ± 14.74 vs 22.67 
± 25.46 pg·ml-1; p = 0.3878 CHO vs CON, respectively) 
were not significantly different prior to carbohydrate or 
placebo supplementation. 
Mean power from the Wingate test for all subjects 
was 633.8 ± 94.52 W, yielding a mean workload of 317.4 
± 47.3 W for each exercise bout. In order for some 
subjects to complete each 3-minute bout, resistance was 
minimally decreased, but the mean workload between 
trials was not significantly different (293.5 ± 7.5 vs 292.6 
± 10.5 W, p = 0.787). Furthermore, HR was not 
significantly different between trials at any time point (p 
> 0.05 between each time point). Total work done and 
exercise heart rates are presented in Table 1. Finally, to 
control for blood volume, hematocrit was assessed before, 
halfway through, and after each exercise session, and no 
significant differences were found (p > 0.05 at each time 
point).  
Fasted blood glucose was significantly higher 
immediately prior to the first bout of exercise  in the CHO 
group but not the CON group when compared to the 
baseline value (138.57 ± 30.71 vs 98.10 ± 15.23, p < 
0.05). Blood glucose was significantly increased 30 min 
after exercise and remained significantly elevated through 
the second exercise bout in the CHO group compared to 
the CON group (Figure 1). This increase in blood glucose 
was accompanied by an increase in plasma insulin at the 
same time point in the CHO group compared to the CON 
group, and continued for the same amount of time as the 
rise in glucose (Figure 2). Plasma visfatin was not 
significantly different between trials at any time point and 
did not differ across time points within either trial (Figure 
3). Finally, plasma visfatin was not significantly 
correlated to blood glucose (r2 = 0.0047, p = 0.626) or 
plasma insulin (r2 = 0.0578, p = 0.554). Plasma visfatin 
was, however, significantly correlated to truncal fat (r2 = 
0.7782, p < 0.05). Lastly, blood lactate was significantly 
elevated after the first bout of exercise (p > 0.05) in both 
trials and remained elevated for the remainder of exercise 
with no further increase or difference between trials 
(Figure 4). 
 
         Table 1. Exercise workload and heart rate (HR). Data are means (±SD).  
 Predicted 
Workload (W) 
CHO Trial 
Workload (W) 
Placebo Trial 
Workload (W) 
CHO Trial 
HR 
Placebo Trial 
HR 
Bout 1 317.4 (47.3) 303.3 (44.0) 302.6 (41.6) 154 (23) 159 (22) 
Bout 2 317.4 (47.3) 294.5 (46.3) 300.3 (50.0) 160 (26) 163 (29) 
Bout 3 317.4 (47.3) 290.7 (45.9) 286.2 (50.2) 170 (17) 162 (33) 
Bout 4 317.4 (47.3) 285.4 (51.4) 281.1 (54.5) 172 (30) 170 (29) 
 
 
 
 
 
                                Figure 1. Plasma visfatin before and after each exercise bout. 
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Figure 2. Blood glucose before and after exercise bout. * Significantly higher than corre-
sponding time point in placebo trial (p < 0.05). 
 
 
 
 
 
Figure 3. Plasma insulin before and after exercise bout. * Significantly higher than cor-
responding time point in placebo trial (p < 0.05). 
 
Discussion 
 
Previous literature suggests that visfatin may play a role 
in glucose metabolism, specifically by acting as an insulin 
mimetic. For example, plasma visfatin levels mirror 
changes in blood glucose following aerobic exercise, and 
in hyperglycemic, insulin-imparied subjects, plasma 
visfatin independently augments glucose uptake (Brema 
et al. 2008; Choi et al. 2007; Haider et al. 2006; Haus et 
al. 2009; Jorge et al. 2011; Park et al. 2013; Rezvan et al. 
2012). Unfortunately, this small amount of existing data 
is not complete. Therefore, the purpose of this study was 
to assess plasma visfatin response to high-intensity exer-
cise and carbohydrate supplementation-induced altera-
tions in normoglycemic, insulin-sensitive subjects. The 
major finding of this study was that visfatin was not af-
fected by changes in plasma glucose due to either carbo-
hydrate supplementation or high-intensity exercise. In 
contrast, after carbohydrate supplementation, plasma 
glucose and insulin significantly increased compared to 
placebo, and these increases were maintained through the 
first two bouts of exercise relative to placebo. Here, this 
maintained increase in plasma glucose most likely was 
due to carbohydrate supplementation and, in turn, an 
alteration in fuel availability during exercise (Jenkins et 
al. 1994; Pirnay et al. 1977). After the second bout of 
exercise, plasma glucose returned to baseline. This clear-
ing of glucose was likely due to increased glucose uptake 
by active skeletal muscle through both insulin-dependent 
and independent mechanisms. Moreover, this glucose 
response is typical of exercise-trained individuals after 
receiving  a  carbohydrate  supplement  prior  to   exercise  
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Figure 4. Blood lactate before and after exercise bout. * Significantly higher than pre-0, 
Pre-15 and Pre-1 values (p < 0.05). 
 
(Jenkins et al. 1994; Jeukendrup et al. 1997; Pedersen et 
al. 2008). Furthermore, an increase in blood lactate was 
seen throughout exercise, which likely is partially due to 
the high-intensity exercise-mediated increase in glycolytic 
rate within skeletal muscle. Despite the increase and 
clearance of blood glucose, plasma visfatin did not 
change. Conversely, insulin responded in a manner simi-
lar to plasma glucose, significantly increasing after sup-
plementation and remaining elevated halfway through the 
exercise trial (compared to placebo). The increase in insu-
lin secretion is likely due to two factors: 1) an increase in 
blood glucose due to carbohydrate ingestion; and 2) an 
increase in transient insulin resistance often seen with 
high-intensity exercise (Ghanbari-Niaki et al. 2010). Dur-
ing high-intensity exercise, insulin resistance often occurs 
partially due to inhibition of insulin signaling by in-
creased levels of catecholamines, growth hormone and 
cortisol (Felsing et al. 1992; Ghanbari-Niaki et al. 2010; 
Jurimae et al. 2009; MacDougall et al. 1977). Although 
insulin resistance, GH, and cortisol were not assessed in 
the current study, these data support that the subjects used 
in the current study were metabolically healthy, exercise 
trained, and thus, a good cohort in which to examine 
plasma visfatin as an insulin mimetic.  
As a speculative insulin mimetic, visfatin should 
follow plasma insulin dynamics. In the current study, 
plasma visfatin was not significantly changed during 
either high-intensity exercise condition, although plasma 
glucose, insulin, and blood lactate were altered by carbo-
hydrate supplementation and/or exercise. The only other 
high-intensity exercise study to investigate plasma visfat-
in showed that plasma visfatin was increased after 7 sets 
of 35 m sprints performed on a treadmill in healthy males 
(Ghanbari-Niaki et al. 2010). This increase in visfatin 
followed the post-exercise increase in insulin and glucose. 
The authors suggested that the increase in visfatin was a 
visfatin-mediated response to increase glucose uptake in 
the face of decreased insulin sensitivity seen with high-
intensity exercise. While the current study also utilized a 
high-intensity model, the duration of exercise bouts was 
significantly longer (3 min compared to 1 min), as was 
the rest time between bouts (6 min compared to 1 min).  
Since plasma visfatin was not different immediate-
ly before or after any of the exercise sessions, one can 
assume that plasma visfatin did not play a significant role 
in glycolytic function in healthy individuals despite al-
terations in exercise metabolism. The reason for this lack 
of change in visfatin, again, may be due to a lower inten-
sity of exercise or shorter rest periods compared to previ-
ous studies that used higher intensity exercise as a treat-
ment (Ghanbari-Niaki et al. 2010). If visfatin does poten-
tially mediate glycolytic function, exercise done at this 
intensity may have been low enough to allow for reliance 
on other substrates. Furthermore, if visfatin acts to in-
crease glucose uptake when insulin function is impaired, 
as previously suggested, there likely was not the same 
transient insulin resistance seen with activity in the cur-
rent study that has been seen in previous studies (Fukuha-
ra et al. 2005; Ghanbari-Niaki et al. 2010). 
The visfatin response to exercise is different in 
moderate endurance exercise. For example, Jurimae et al. 
showed plasma visfatin decreased 30 min after 2 hr of 
rowing, which was considered to be due to increased 
uptake of plasma visfatin by subcutaneous adipose tissue 
(2009). While it is well known that subcutaneous adipose 
tissue is actively involved in visfatin production and se-
cretion, the evidence for visfatin uptake into adipose tis-
sue is lacking. Moderate intensity exercise initiates an 
increase in subcutaneous adipose tissue visfatin mRNA; 
however, increases in plasma visfatin do not follow 
(Frydelund-Larsen et al. 2007), suggesting that while 
mRNA transcripts for visfatin are increased intracellular-
ly, the translation to protein is not occurring at the same 
level or that any visfatin produced is not being released 
into the systemic circulation. Arguably, the increase in 
subcutaneous mRNA could have a local autocrine and/or 
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paracrine effect that may enhance insulin sensitivity after 
exercise. While previous studies suggest that visfatin may 
play a role in plasma glucose regulation during high-
intensity running sprints and moderate-intensity endur-
ance exercise, the present study suggests otherwise.   
Another potential interaction between visfatin and 
glucose regulation could be its effect on metabolism as an 
enzyme in the NAD salvage pathway. Some studies have 
shown that enhancing caloric restriction and chronic exer-
cise both lead to increases in mitochondrial respiration 
partially by increasing NAD availability through in-
creased activation of visfatin (as NAMPT) both in vivo 
and in cell culture (Revollo et al. 2004; Rongvaux et al. 
2008; Yang et al. 2007; Hsu et al. 2009). Frederick et al. 
recently showed that enhancing NAD synthesis specifical-
ly within skeletal muscle did not lead to any changes in 
oxidative metabolism in healthy subjects (2015). Those 
results suggest that the role of visfatin (as either a hor-
mone or an enzyme) may likely be important in maintain-
ing mitochondrial respiration as well as glucose intake in 
individuals for whom glucose uptake is impaired, but not 
in a healthy population.   
The acute effect of carbohydrate intake on plasma 
visfatin is not clear. Bala et al. (2011), showed plasma 
visfatin to be significantly decreased after ingestion of 
carbohydrate and this decrease was more pronounced in 
individuals with a higher BMI. The subjects in this study, 
however, were not screened for obesity or hyperglycemia. 
Alexiadou et al., on the other hand, found plasma visfatin 
to be unchanged with glucose intake in type I diabetics 
(2012). Lastly, Zhaoxia et al. found visfatin levels to 
increase in gestationally diabetic women after an oral 
glucose tolerance. These results again suggest that visfatin 
may mediate glucose uptake when insulin function is 
impaired (Zhaoxia et al. 2012). The reason for the dis-
crepancy in previous studies is likely due to the heteroge-
neity of subjects used in the different studies.    
In the current study, plasma visfatin was un-
changed by carbohydrate intake. Because the subjects 
used in this study were insulin sensitive, plasma visfatin 
does not appear to be affected by alterations in plasma 
glucose in healthy young men. To our knowledge, this is 
the first study to examine the effect of carbohydrate in-
take on plasma visfatin in trained, healthy young males. 
Although no change in plasma visfatin response was 
observed in the current study, a cellular visfatin response 
cannot be excluded. In fact, multiple studies have shown 
that alterations in cellular visfatin protein levels enhance 
glucose uptake, including skeletal muscle (Fukuhara et al. 
2005; Revollo et al. 2007; Song et al. 2008; Xie et al. 
2007). Because no cellular analyses were performed in 
the current study, it is not possible to say if visfatin con-
tent and/or activity were higher or lower in skeletal mus-
cle after carbohydrate ingestion or high-intensity exercise. 
This potential relationship should be further assessed, 
since this mechanism holds promise as a therapeutic tar-
get for insulin resistance-based pharmaceuticals.  
Because visfatin can be secreted from adipose tis-
sue, the correlation between truncal fat and plasma visfat-
in was also examined in the current study. While previous 
studies have not assessed truncal fat, the relationship 
between visceral fat and plasma visfatin has been debated.  
Fukuhara et al. (2005) showed a direct correlation be-
tween visceral fat and plasma visfatin, while Chang et al. 
(2010) found no correlation. Although the study by Fuku-
hara et al. (2005) was later retracted for reasons unrelated 
to this part of the study, the authors stood by their find-
ings related to visceral fat and visfatin. In the current 
study, a significant correlation was found between truncal 
fat and plasma visfatin (r = 0.7782, p < 0.05). Visceral fat 
was not directly assessed, but truncal fat has been shown 
to be a direct indicator of visceral fat (Dwimartutie et al. 
2010; Parikh et al. 2007). Although all subjects had a 
body fat percentage below 20, this direct correlation may 
partially explain the large standard deviation seen in the 
current study (resting visfatin: 11.80 ± 10.15). Further-
more, this is the first study to show a significant correla-
tion between plasma visfatin and truncal fat in healthy 
subjects. 
Every attempt was made to control confounding 
variables as much as possible in the current study. There 
were, however, some limitations to this study. First, not 
all subjects were cyclists. Subjects were excluded if they 
did not exercise at a high-intensity at least three times per 
week. This led to a well-trained subject pool, but some 
subjects (n = 6) were experienced cyclists (cycling at least 
100 miles/week). As the mode of exercise was a cycle 
ergometer, this may have altered the exercise response in 
some subjects.  Also, carbohydrate supplementation was 
not based on body weight, although there was not a sig-
nificant difference regarding grams of carbohydrate per 
kg of body weight (641 mg ± 68 mg) between subjects. 
The dosage of carbohydrate was based on a previous 
study, which found 50 g of carbohydrates elevated blood 
glucose in healthy individuals (Kraemer et al. 2011), as 
well as an unpublished pilot study. While supplementa-
tion was not based on body weight, blood glucose was 
significantly increased (33.12 ± 1.24 %) beyond resting 
levels in all individuals after carbohydrate supplementa-
tion. As the purpose of this study was to assess plasma 
visfatin changes in response to blood glucose changes, the 
carbohydrate supplement used was an adequate stimulus.  
Despite these limitations, the present study shows that in 
healthy young men, plasma visfatin is not affected by 
carbohydrate supplementation or acute intermittent, high-
intensity exercise. Future studies are needed to determine 
the relationship of visfatin and blood glucose regulation 
on an intracellular level as well as visfatin’s relationship 
to other hormones associated with blood glucose regula-
tion during exercise. 
 
Conclusion 
 
The present study demonstrates that no significant rela-
tionship exists between plasma glucose and plasma visfat-
in in young, exercise-trained, insulin-sensitive males, and 
that visfatin likely does not mediate glucose uptake since 
plasma visfatin did not change despite changes in blood 
glucose, plasma insulin, or lactate.  The lack of effect in 
this population suggests the possibility that plasma visfat-
in may only be an effective contributor to glucose control 
when insulin function is impaired or possibly through its 
Mellick et al. 
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enzymatic regulation of NAD salvage.  Still, future re-
search is needed to further examine the basic biological 
role of visfatin in the human. 
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Key points 
 
• Plasma visfatin was not affected by exercise or car-
bohydrate supplementation.  
• Plasma visfatin was significantly correlated to ab-
dominal fat. 
• Plasma visfatin did not follow a similar pattern to 
blood glucose or plasma insulin as has been shown in 
previous studies.  
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